febril
neutropenia
common
complic
children
undergo
chemotherapi
treatment
malign
septicemia
potenti
lethal
difficult
rule
onset
fever
empir
treatment
broadspectrum
antibiot
promptli
initi
base
wide
indic
howev
case
underli
caus
fever
identifi
febril
neutropenia
associ
long
hospit
neg
social
effect
child
famili
addit
hospit
use
broadspectrum
antibiot
increas
patient
risk
subsequ
infect
antibioticresist
bacteria
fungal
infect
better
understand
etiolog
febril
neutropenia
thu
need
order
decreas
unnecessari
hospit
excess
antibiot
use
infect
respiratori
virus
common
morbid
children
respiratori
virus
like
play
signific
role
childhood
febril
neutropenia
advanc
molecular
method
increas
sensit
viral
diagnost
test
recent
studi
report
detect
respiratori
virus
nasopharynx
childhood
febril
neutropenia
episod
use
realtim
polymeras
chain
reaction
pcr
howev
clinic
signific
posit
pcr
find
unclear
respiratori
virus
also
detect
asymptomat
immunocompet
children
addit
respiratori
virus
detect
week
first
infect
suggest
prolong
viral
shed
describ
result
longitudin
studi
involv
repeat
sampl
assess
broad
panel
respiratori
virus
pcr
clarifi
whether
respiratori
virus
play
causal
role
childhood
febril
neutropenia
children
age
year
treat
malign
childhood
cancer
unit
astrid
lindgren
children
hospit
stockholm
sweden
januari
june
elig
enrol
studi
patient
met
criteria
febril
neutropenia
ask
particip
patient
could
enrol
multipl
time
recurr
episod
febril
neutropenia
occur
studi
period
enrol
new
episod
patient
need
afebril
hour
complet
antibiot
treatment
previou
episod
febril
neutropenia
febril
neutropenia
defin
bodi
temperatur
one
occas
two
occas
least
minut
apart
combin
absolut
neutrophil
count
either
one
occas
declin
less
subsequ
period
oral
written
inform
regard
studi
provid
patient
prior
enrol
sign
consent
obtain
caretak
studi
approv
region
ethic
review
board
stockholm
nasopharyng
aspir
npa
collect
within
hour
onset
fever
npa
dilut
approxim
ml
salin
immedi
sent
accredit
karolinska
univers
laboratori
iso
microbiolog
analysi
viral
nucleic
acid
extract
npa
magattract
viru
mini
kit
qiagen
sollentuna
sweden
analyz
inhous
realtim
pcr
follow
virus
adenoviru
hadv
bocaviru
hbov
coronavirus
hcov
enteroviru
ev
influenza
viru
includ
b
flu
metapneumoviru
hmpv
parainfluenza
virus
piv
respiratori
syncyti
viru
rsv
rhinoviru
rv
semiquantit
assay
use
actual
cycl
thresholdsvalu
ctvalu
provid
howev
npa
valid
quantit
data
studi
subject
initi
test
posit
one
respiratori
virus
followup
sampl
collect
time
next
visit
hospit
followup
sampl
collect
regardless
patient
absolut
neutrophil
count
symptom
analyz
manner
first
sampl
howev
patient
new
episod
febril
neutropenia
time
followup
sampl
consid
followup
sampl
new
episod
sampl
requir
addit
followup
sampl
new
episod
test
posit
respiratori
viru
rvev
genotyp
perform
sequenc
sampl
pcrposit
rv
andor
ev
use
recent
publish
method
base
method
primer
origin
publish
wisdom
et
al
briefli
viral
rna
extract
describ
sampl
rneasi
lipid
tissu
mini
kit
qiagen
sollentuna
sweden
use
sampl
neg
pcr
magattract
extract
rna
use
nest
revers
transcriptas
rt
pcr
onestep
superscriptplatinum
taq
life
technolog
stockholm
sweden
first
outer
pcr
platinum
taq
second
nest
pcr
sequenc
done
abi
instrument
rvev
speci
type
determin
maximum
likelihood
phylogenet
tree
construct
use
phyml
sequenc
deposit
genbank
access
number
rva
rvc
two
rvc
sampl
submit
genbank
sequenc
suboptim
qualiti
due
probabl
infect
one
rv
genotyp
blood
cultur
collect
patient
detect
bacteri
infect
analyz
karolinska
univers
laboratori
per
routin
clinic
procedur
clinic
data
includ
result
biochem
microbiolog
analys
patient
characterist
treatment
febril
episod
fever
characterist
durat
hospit
collect
medic
record
data
analyz
use
graphpad
prism
softwar
graphpad
prism
san
diego
ca
fisher
exact
test
mannwhitney
u
test
use
group
comparison
categor
continu
data
respect
pvalu
less
consid
statist
signific
total
patient
repres
episod
febril
neutropenia
enrol
studi
five
episod
exclud
due
incomplet
sampl
therefor
analys
includ
patient
episod
febril
neutropenia
rang
episod
per
patient
day
episod
characterist
studi
particip
list
tabl
median
age
across
episod
year
rang
year
episod
occur
femal
patient
undergo
treatment
hematolog
malign
episod
solid
tumor
episod
respiratori
symptom
note
episod
febril
neutropenia
tabl
least
one
respiratori
viru
identifi
episod
singl
respiratori
viru
detect
episod
tabl
multipl
virus
rang
virus
detect
two
episod
wherea
copres
respiratori
viru
septicemia
detect
three
episod
tabl
episod
rv
frequent
detect
respiratori
viru
n
follow
hcov
n
flu
n
rsv
n
piv
n
hmpv
n
hbov
n
hadv
n
tabl
virusposit
episod
patient
year
age
common
respiratori
viru
identifi
group
year
age
rv
n
follow
piv
n
hcov
n
hadv
n
hbov
n
rsv
n
addit
one
episod
copres
respiratori
viru
septicemia
identifi
group
year
age
episod
involv
respiratori
viral
infect
ie
infect
either
singl
respiratori
viru
multipl
respiratori
virus
respiratori
symptom
detect
tabl
symptom
appar
four
episod
involv
rv
one
episod
involv
hcov
tabl
episod
involv
respiratori
symptom
report
appear
respiratori
symptom
time
fever
onset
tabl
remain
five
episod
respiratori
symptom
appear
day
onset
fever
five
episod
repres
one
flu
b
four
rv
tabl
bacteri
blood
cultur
posit
episod
febril
neutropenia
five
cultur
exclud
analysi
defin
septicemia
determin
either
contamin
clinic
relev
treat
clinician
andor
laboratori
micrococcu
speci
n
coagulaseneg
staphylococcu
n
staphylococcu
epidermidi
n
unspecifi
gramposit
bacteria
n
eight
episod
therefor
consid
true
septicemia
five
episod
involv
septicemia
tabl
ie
test
neg
respiratori
virus
pcr
three
episod
involv
copres
respiratori
viru
septicemia
gramposit
bacteria
staphylococcu
epidermidi
n
alpha
streptococcu
n
detect
three
episod
one
episod
also
posit
gramneg
bacteria
escherichia
coli
three
episod
involv
copres
respiratori
viru
septicemia
patient
treat
hematolog
malign
respiratori
symptom
tabl
virus
found
group
rv
n
hbov
n
tabl
episod
respiratori
viru
septicemia
detect
febril
episod
therefor
defin
fever
unknown
origin
tabl
compar
episod
involv
respiratori
viral
infect
ie
infect
either
singl
respiratori
viru
multipl
respiratori
virus
episod
involv
septicemia
fever
unknown
origin
statist
signific
differ
observ
respect
age
gender
day
fever
maximum
temperatur
tabl
howev
presenc
respiratori
symptom
significantli
higher
episod
involv
respiratori
viral
infect
compar
episod
involv
septicemia
fever
unknown
origin
p
p
respect
episod
respiratori
viral
infect
also
often
treat
hematolog
malign
compar
fever
unknown
origin
episod
p
episod
involv
septicemia
significantli
day
antibiot
median
day
rang
day
p
longer
hospit
median
day
rang
day
p
compar
episod
respiratori
viral
infect
median
day
rang
day
versu
median
day
rang
day
respect
episod
involv
septicemia
higher
maximum
crpmedian
median
mgl
rang
mgl
compar
episod
involv
respiratori
viral
infect
median
mgl
rang
differ
statist
signific
p
followup
sampl
collect
virusposit
episod
eight
sampl
repres
new
episod
febril
neutropenia
infect
resolv
episod
median
day
rang
day
followup
six
episod
exhibit
persist
rv
one
episod
exhibit
persist
hcov
median
followup
time
day
rang
day
day
respect
seven
episod
three
involv
rv
present
new
episod
febril
neutropenia
except
episod
involv
hcov
present
new
persist
respiratori
symptom
tabl
new
respiratori
viru
detect
six
followup
sampl
flu
n
rv
n
hcov
n
rsv
n
six
episod
except
one
involv
rv
exhibit
respiratori
symptom
one
flu
repres
new
episod
febril
neutropenia
rv
genotyp
perform
determin
whether
episod
exhibit
repeat
pcr
posit
involv
new
persist
infect
sampl
rvposit
episod
success
sequenc
result
identif
rva
rvc
speci
tabl
sequenc
four
patient
repres
six
episod
remain
rvposit
followup
tabl
one
patient
rvposit
three
followup
sampl
howev
sequenc
reveal
two
followup
sampl
contain
new
rv
speci
fig
sequenc
also
reveal
three
remain
patient
genotyp
fig
rvc
clear
time
followup
tabl
four
persist
episod
involv
rv
associ
rva
infect
tabl
best
knowledg
first
longitudin
studi
assess
respiratori
viral
persist
children
present
febril
neutropenia
found
respiratori
viral
infect
common
children
febril
neutropenia
major
episod
accompani
respiratori
tract
symptom
infect
resolv
followup
major
episod
result
support
theori
hold
causal
relationship
respiratori
viral
infect
episod
febril
neutropenia
prove
theori
requir
longitudin
studi
asymptomat
neutropen
control
cohort
addit
prolong
viral
persist
regard
respiratori
tract
infect
seem
uncommon
children
undergo
chemotherapi
treatment
malign
previou
studi
detect
respiratori
virus
episod
febril
neutropenia
subsequ
studi
confirm
find
detect
rate
rang
detect
rate
current
studi
consist
earlier
studi
crucial
correctli
diagnos
febril
neutropenia
immunosuppress
children
infect
virus
bacteria
fungi
fatal
group
patient
clinic
signific
singl
timepoint
pcr
find
certain
pathogen
debat
studi
immunocompet
children
report
virus
hbov
hcov
rv
detect
asymptomat
children
rate
rang
could
suggest
prolong
viral
shed
earlier
infect
incub
period
prior
symptomat
asymptomat
infect
clarifi
issu
longitudin
studi
appropri
control
group
need
rhedin
et
al
conduct
casecontrol
studi
investig
etiolog
role
respiratori
virus
group
children
respiratori
tract
symptom
seek
medic
care
pediatr
emerg
center
control
group
consist
children
routin
visit
child
welfar
center
vaccin
within
childhood
immun
program
detect
rate
respiratori
virus
control
group
high
rv
hcov
commonli
detect
virus
asymptomat
children
hmpv
piv
rsv
detect
rare
author
conclud
hmpv
piv
rsv
play
etiolog
role
suggest
find
rv
hcov
must
care
interpret
chose
longitudin
design
present
studi
found
infect
resolv
median
followup
time
day
addit
two
rv
infect
identifi
followup
repres
new
speci
rv
previou
infect
increas
proport
resolv
infect
one
major
limit
current
studi
lack
control
cohort
neutropen
patient
without
fever
address
question
whether
respiratori
virus
frequent
found
asymptomat
immunosuppress
children
howev
use
longitudin
design
allow
us
collect
followup
sampl
patient
without
respiratori
symptom
five
patient
first
sampl
two
patient
followup
sampl
posit
respiratori
viru
without
presenc
respiratori
symptom
suggest
frequenc
asymptomat
infect
low
group
patient
interestingli
rv
detect
five
seven
episod
hcov
detect
two
line
studi
presenc
respiratori
symptom
significantli
higher
episod
involv
respiratori
viral
infect
compar
episod
involv
septicemia
fever
unknown
origin
symptom
appear
onset
fever
major
episod
peck
et
al
investig
incid
respiratori
viru
patient
receiv
hematopoiet
stem
cell
transplant
use
longitudin
collect
respiratori
tract
sampl
regardless
symptom
line
result
major
respiratori
virus
detect
could
correl
respiratori
tract
symptom
except
piv
detect
asymptomat
patient
infect
rv
hcov
investig
studi
addit
high
viral
load
correl
symptom
realtimepcr
techniqu
valid
use
report
clinic
viral
load
thu
present
ctvalu
must
interpret
extrem
caution
nevertheless
ctvalu
observ
episod
febril
neutropenia
suggest
high
viral
load
tabl
consid
togeth
data
suggest
respiratori
virus
play
etiolog
role
febril
neutropenia
result
interpret
care
especi
regard
rv
commonli
detect
asymptomat
patient
despit
abovement
limit
believ
find
respiratori
viru
togeth
clinic
paramet
respiratori
symptom
neg
blood
cultur
hour
histori
short
durat
myelosuppress
may
help
reduc
treatment
time
broadspectrum
antibiot
need
prolong
hospit
particularli
interest
rv
studi
frequent
detect
viru
still
detect
followup
report
asymptomat
immunocompet
children
clinic
impact
rv
correl
sever
respiratori
diseas
children
year
age
studi
c
speci
rv
identifi
speci
believ
pathogen
strongli
associ
hospit
treatment
rvb
rva
rvc
caus
upper
lower
respiratori
tract
infect
frequent
detect
speci
anoth
studi
investig
rv
infect
immunosuppress
children
case
rvb
report
studi
patient
upper
respiratori
tract
infect
studi
cohort
episod
detect
rv
infect
hospit
result
febril
neutropenia
therefor
sever
diseas
relat
rv
speci
difficult
evalu
respiratori
virus
shed
time
thoroughli
investig
immunosuppress
children
earlier
studi
rsv
shown
prolong
viral
shed
immunosuppress
children
compar
healthi
children
martin
et
al
conduct
longitudin
studi
healthi
immunocompet
children
attend
daycar
center
found
prolong
shed
ie
persist
viru
day
virus
examin
except
flu
b
jartti
et
al
report
shed
time
week
ev
rv
respect
immunocompet
children
howev
rv
sequenc
studi
therefor
unclear
whether
sampl
week
repres
new
genotyp
rv
anoth
studi
report
prolong
persist
day
rv
strain
uncommon
shed
time
special
interest
cohort
immunosuppress
children
viral
shed
necessit
isol
immunosuppress
children
design
present
studi
allow
us
determin
exact
shed
time
major
limit
howev
clearanc
virus
except
rva
hcov
median
followup
time
day
togeth
respiratori
symptom
appear
time
fever
onset
major
patient
suggest
shed
time
virus
flu
hmpv
rsv
piv
limit
rv
genotyp
detect
followup
sampl
four
episod
followup
time
day
furthermor
five
patient
posit
rv
report
symptom
appear
day
longer
fever
onset
could
indic
longer
shed
time
rv
line
result
studi
immunocompet
children
howev
need
address
addit
studi
repeat
followup
sampl
prefer
weekli
basi
hbov
associ
acut
wheez
immunocompet
children
immunosuppress
children
hbov
detect
togeth
virus
also
detect
repeatedli
suggest
prolong
shed
reactiv
studi
hbov
detect
twice
hadv
rsv
rv
one
episod
togeth
septicemia
anoth
episod
episod
involv
respiratori
symptom
followup
sampl
hbov
longer
detect
previou
studi
detect
hbov
three
episod
togeth
one
viru
rv
septicemia
agent
make
difficult
ascertain
clinic
relev
data
strengthen
evid
suggest
respiratori
virus
play
etiolog
role
febril
neutropenia
children
receiv
treatment
malign
confirm
futur
studi
find
report
implic
clinic
manag
patient
find
could
lead
decreas
durat
hospit
treatment
broadspectrum
antibiot
lead
posit
social
effect
child
famili
well
decreas
risk
subsequ
infect
antibioticresist
bacteria
